Clinical trial
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
NCT00215800 · AIM ImmunoTech Inc., Industry · Completed
Key facts
| NCT number | NCT00215800 |
|---|---|
| Title | The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome |
| Official title | A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) |
| Lead sponsor | AIM ImmunoTech Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis |
| Intervention type | Drug |
| Interventions | Ampligen |
| Enrollment | 234 |
| Start date | Dec 1, 1998 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 17, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: